FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mario Delgado

Research Profile

Chemicals & Drugs

Living Beings

Anatomy

Physiology

Co-author Network

Publications

TOP 3
Sharma Vikas; Mario Delgado; Doina Ganea
VIP protects Th2 cells by downregulating granzyme B expression.
Mario Delgado; Elena Gonzalez-Rey; Doina Ganea
Vasoactive intestinal peptide: the dendritic cell --> regulatory T cell axis.
Sharma Vikas; Mario Delgado; Doina Ganea
Granzyme B, a new player in activation-induced cell death, is down-regulated by vasoactive intestinal peptide in Th2 but not Th1 effectors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mario Delgado (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2006: Sharma Vikas; Mario Delgado; Doina Ganea
VIP protects Th2 cells by downregulating granzyme B expression.
Annals of the New York Academy of Sciences 2006;1070():540-4.
2006: Mario Delgado; Elena Gonzalez-Rey; Doina Ganea
Vasoactive intestinal peptide: the dendritic cell --> regulatory T cell axis.
Annals of the New York Academy of Sciences 2006;1070():233-8.
2006: Sharma Vikas; Mario Delgado; Doina Ganea
Granzyme B, a new player in activation-induced cell death, is down-regulated by vasoactive intestinal peptide in Th2 but not Th1 effectors.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(1):97-110.
2005: Mario Delgado; Elena Gonzalez-Rey; Doina Ganea
The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(11):7311-24.
2005: Mario Delgado; Alejo Chorny; Elena Gonzalez-Rey; Doina Ganea
Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo.
Journal of leukocyte biology 2005;78(6):1327-38.
2003: Mario Delgado; Doina Ganea
Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2003;17(13):1922-4.
2003: Mario Delgado; Doina Ganea
Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2003;17(8):944-6.
2003: Mario Delgado; Doina Ganea
Vasoactive intestinal peptide inhibits IL-8 production in human monocytes by downregulating nuclear factor kappaB-dependent transcriptional activity.
Biochemical and biophysical research communications 2003;302(2):275-83.
2003: Doina Ganea; R Rodriguez; Mario Delgado
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity.
Cellular and molecular biology (Noisy-le-Grand, France) 2003;49(2):127-42.
2003: Mario Delgado; Doina Ganea
Vasoactive intestinal peptide inhibits IL-8 production in human monocytes.
Biochemical and biophysical research communications 2003;301(4):825-32.
2003: Doina Ganea; Mario Delgado
The neuropeptides VIP/PACAP and T cells: inhibitors or activators?
Current pharmaceutical design 2003;9(12):997-1004.
2003: Mario Delgado; Javier Leceta; Doina Ganea
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia.
Journal of leukocyte biology 2003;73(1):155-64.
2002: Mario Delgado; Javier Leceta; Doina Ganea
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2002;16(13):1844-6.
2002: Mario Delgado; G Miller Jonakait; Doina Ganea
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
Glia 2002;39(2):148-61.
2002: Doina Ganea; Mario Delgado
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity.
Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists 2002;13(3):229-37.
2001: Mario Delgado; Doina Ganea
Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo.
Journal of immunology (Baltimore, Md. : 1950) 2001;167(2):966-75.
2001: Mario Delgado; Doina Ganea
Cutting edge: is vasoactive intestinal peptide a type 2 cytokine?
Journal of immunology (Baltimore, Md. : 1950) 2001;166(5):2907-12.
2001: Mario Delgado; Doina Ganea
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3.
Journal of immunology (Baltimore, Md. : 1950) 2001;166(2):1028-40.
2001: Mario Delgado; Doina Ganea
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1.
The Journal of biological chemistry 2001;276(1):369-80.
2001: Doina Ganea; Mario Delgado
Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP.
Archivum immunologiae et therapiae experimentalis 2001;49(2):101-10.
2001: Mario Delgado; Doina Ganea
VIP and PACAP inhibit Fas ligand-mediated bystander lysis by CD4(+) T cells.
Journal of neuroimmunology 2001;112(1-2):78-88.
2000: Mario Delgado; Doina Ganea
Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages.
Journal of neuroimmunology 2000;110(1-2):97-105.
2000: Mario Delgado; Doina Ganea
Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.
Journal of immunology (Baltimore, Md. : 1950) 2000;165(6):3051-7.
2000: W Sun; I Tadmori; L Yang; Mario Delgado; Doina Ganea
Vasoactive intestinal peptide (VIP) inhibits TGF-beta1 production in murine macrophages.
Journal of neuroimmunology 2000;107(1):88-99.
2000: Mario Delgado; Doina Ganea
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
Journal of immunology (Baltimore, Md. : 1950) 2000;165(1):114-23.
2000: Mario Delgado; Doina Ganea
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(3):1200-10.
2000: Mario Delgado; Javier Leceta; W Sun; Rosa P Gomariz; Doina Ganea
VIP and PACAP induce shift to a Th2 response by upregulating B7.2 expression.
Annals of the New York Academy of Sciences 2000;921():68-78.
1999: Mario Delgado; Doina Ganea
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB and Ets activation.
The Journal of biological chemistry 1999;274(45):31930-40.
1999: Mario Delgado; W Sun; Javier Leceta; Doina Ganea
VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(8):4213-23.
1999: Mario Delgado; Javier Leceta; Rosa P Gomariz; Doina Ganea
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(7):3629-35.
1999: Mario Delgado; EJ Munoz-Elias; Rosa P Gomariz; Doina Ganea
VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells.
Journal of neuroimmunology 1999;96(2):167-81.
1999: Mario Delgado; EJ Munoz-Elias; Rosa P Gomariz; Doina Ganea
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(8):4685-96.
1999: Mario Delgado; EJ Munoz-Elias; Rosa P Gomariz; Doina Ganea
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(3):1707-16.
1999: Mario Delgado; EJ Munoz-Elias; C Martinez; Rosa P Gomariz; Doina Ganea
VIP and PACAP38 modulate cytokine and nitric oxide production in peritoneal macrophages and macrophage cell lines.
Annals of the New York Academy of Sciences 1999;897():401-14.
1998: Mario Delgado; EJ Munoz-Elias; Y Kan; I Gozes; M Fridkin; Douglas E Brenneman; Rosa P Gomariz; Doina Ganea
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun.
The Journal of biological chemistry 1998;273(47):31427-36.
1996: M C Johnson; R J McCormack; Mario Delgado; C Martinez; Doina Ganea
Murine T-lymphocytes express vasoactive intestinal peptide receptor 1 (VIP-R1) mRNA.
Journal of neuroimmunology 1996;68(1-2):109-19.
1996: Mario Delgado; C Martinez; M C Johnson; Rosa P Gomariz; Doina Ganea
Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes.
Journal of neuroimmunology 1996;68(1-2):27-38.